AI assistant
Quantum Biopharma Ltd. — Regulatory Filings 2022
May 31, 2022
34475_ffr_2022-05-31_e2412bbf-597f-4940-8449-9855797109fa.zip
Regulatory Filings
Open in viewerOpens in your device viewer
6-K 1 a52734608.htm FSD PHARMA INC. 6-K Licensed to: businesswire Document created using EDGARfilings PROfile 8.1.0.0 Copyright 1995 - 2022 Broadridge
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of: May 2022
Commission File Number: 001-39152
FSD PHARMA INC.
(Translation of registrant’s name into English)
199 Bay St., Suite 4000
Toronto, Ontario M5L 1A9, Canada
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| /s/ Nathan Coyle |
|---|
| Nathan Coyle, Chief Financial Officer |
EXHIBIT INDEX
| Exhibit | Description |
|---|---|
| 99.1 | Press Release – Dated May 31, 2022 FSD Pharma Files Investigational New Drug |
| Application (“IND”) with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate Updates |